mRNA alternative: Novavax finally scores EUA for primary Covid-19 vaccine series
Almost 7 months after submitting its EUA application — meaning the FDA’s review took a few months shorter than a standard vaccine review — Novavax on Wednesday finally captured an elusive goal, winning an EUA for its 2-dose primary series of its protein-based vaccine for adults to prevent Covid-19.
While some have sought an alternative to the mRNA-based Covid vaccines from Pfizer/BioNTech and Moderna, both of which have now gone through FDA’s full approval process (EUA ≠ Approval), others question the need for an option like Novavax’s that may end up being less effective than its competitors. Johnson & Johnson recently all but pulled its one-dose version from the US market after safety risks arose.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters